Ireland’s Rare Disease Crisis: Families Fight HSE for Lifesaving Drugs
HSE puts life-altering treatment on hold
The Health Service Executive (HSE) Drugs Group has deferred a decision on the approval of a treatment for Friedreich’s ataxia. This move leaves Irish families facing prolonged uncertainty regarding access to a therapy for the progressive, life-shortening condition. The committee, which evaluates the clinical and economic viability of new medications for the Irish health service, requested further research before determining whether to provide the drug to patients.
Friedreich’s ataxia is a rare, debilitating genetic disease that causes nervous system damage and movement problems. For affected families, the delay represents a significant barrier to care.
A race against a progressive disease
A Cork-based family is currently seeking access to the drug for their second son, who has been diagnosed with the same condition that previously affected his sibling. The family has publicly expressed their frustration, stating that “time is running out” as they watch the disease progress.
This situation is mirrored by other patients, including a young woman who has campaigned for the drug to be made available. Her advocacy has centered on the question of the value placed on the lives of those suffering from rare, life-limiting conditions. The ongoing delay has drawn sharp criticism from campaigners who argue that the current HSE evaluation process for rare disease drugs is inherently slow and ill-equipped to handle the needs of patients with rapidly advancing illnesses.
Stalled evidence and institutional limbo
The HSE Drugs Group is responsible for assessing whether the cost-effectiveness and clinical data of a drug justify its inclusion in the state-funded treatment list. By deferring the decision, the group has signaled that the current body of evidence provided by the manufacturer is insufficient to support a positive recommendation at this time.
The deferral is not a final rejection, but it halts any immediate possibility of state-funded access. For patients and their families, this institutional pause creates a period of limbo, as they must wait for the outcome of additional research and subsequent committee reviews.
No timeline for medical relief
The HSE has not provided a specific timeline for when the additional research will be submitted or when the Drugs Group will reconvene to review the new data. The matter remains under assessment by the health authority, with no current mechanism in place for the immediate provision of the treatment while the review process continues.